Handelsbanken Fonder AB Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Handelsbanken Fonder AB bought a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,500 shares of the company’s stock, valued at approximately $205,000.

A number of other institutional investors also recently modified their holdings of the stock. Eventide Asset Management LLC increased its position in Zentalis Pharmaceuticals by 13.6% in the third quarter. Eventide Asset Management LLC now owns 7,814,039 shares of the company’s stock worth $156,750,000 after purchasing an additional 936,236 shares during the period. Vanguard Group Inc. lifted its holdings in Zentalis Pharmaceuticals by 6.2% in the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after buying an additional 307,490 shares during the period. Federated Hermes Inc. boosted its stake in Zentalis Pharmaceuticals by 10.9% in the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after acquiring an additional 212,872 shares during the last quarter. Wellington Management Group LLP grew its holdings in Zentalis Pharmaceuticals by 0.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock worth $38,457,000 after acquiring an additional 8,661 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Zentalis Pharmaceuticals by 8.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,064 shares of the company’s stock worth $8,868,000 after acquiring an additional 36,219 shares during the period.

Zentalis Pharmaceuticals Stock Up 5.4 %

Shares of NASDAQ:ZNTL opened at $11.71 on Friday. The firm has a market cap of $831.53 million, a price-to-earnings ratio of -2.58 and a beta of 1.82. Zentalis Pharmaceuticals, Inc. has a 12 month low of $9.56 and a 12 month high of $31.46. The company’s fifty day simple moving average is $13.89 and its 200 day simple moving average is $13.63.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09. Research analysts expect that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ZNTL has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush boosted their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.57.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.